Rx Propellant, backed by Actis and General Atlantic, is investing $100 million in a groundbreaking life sciences campus in Hyderabad's Genome Valley. The project will develop over 1 million square feet of advanced laboratory infrastructure, catering to both Indian and global life sciences companies. This strategic investment highlights the growing potential of India's research and development ecosystem. CEO Ashish Singh emphasized the importance of evolving infrastructure to support the sector's decisive scale-up. The campus will offer scalable, high-quality R&D spaces with fully compliant buildings and advanced electromechanical services. This development follows the success of Rx Propellant's previous campuses in the region, which are already fully leased by prominent global and domestic life sciences firms.
